Amlodipine News and Research

RSS

Gene variations associated with effectiveness of blood pressure medications

Patients with hypertension and certain gene variations experienced varying results with some blood pressure medications, suggesting matching a patient's genotype with certain hypertension medications could result in more favorable outcomes, according to a study in the January 23 issue of JAMA: The Journal of the American Medical Association.

23 Jan 2008

FDA to review potential anti-arrhythmic claims for Ranexa

CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).

10 Dec 2007

Caraco Pharmaceutical Labs announces FDA approval to market generic Norvasc

Caraco Pharmaceutical Laboratories has announced that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Amlodipine Besylate Tablets, 2.5 mg, 5 mg, and 10 mg (Amlodipine).

5 Dec 2007

Lupin receives approval for Amlodipine tablets

Lupin Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

18 Jul 2007

Ranbaxy receives approval to manufacture and market Amlodipine Besylate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), has announced that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

11 Jul 2007

Roxane Laboratories announces launch of Amlodipine Besylate tablets

Roxane Laboratories, Inc. has announced the approval of its Abbreviated New Drug Application (ANDA) for Amlodipine Besylate Tablets, 2.5mg, 5mg, and 10mg by the U.S. Food and Drug Administration.

10 Jul 2007

Ranbaxy receives tentative approval to manufacture Amlodipine Besylate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

23 Jun 2007

Combination of medicines best for blood pressure control

Millions of Americans take medications for hypertension but do not achieve control of their blood pressure.

22 May 2007

Single-tablet combination of atorvastatin and amlodipine for high blood pressure effective

Adults with high blood pressure and additional risk factors for heart disease may benefit more from taking one tablet rather than two, if their current treatment combines the lipid-lowering medication atorvastatin with the blood pressure-lowering medication amlodipine, researchers reported at the American Heart Association's 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke.

16 May 2007

FDA confirms Mylan's status as only approved ANDA for all strengths of Amlodipine Besylate tablets

Mylan Laboratories has announced that the U.S. Food and Drug Administration (FDA) has confirmed Mylan's current status as the only approved ANDA for all strengths of Amlodipine Besylate Tablets.

20 Apr 2007

U.S. District Court grants Mylan extension for consideration of Amlodipine Besylate exclusivity

Mylan Laboratories has announced that the U.S. District Court for the District of Columbia has extended the deadlines pertaining to Mylan's request for a temporary restraining order in its lawsuit seeking to stop the U.S. Food and Drug Administration (FDA) from approving any other Amlodipine Besylate abbreviated new drug applications (ANDAs).

11 Apr 2007

Pfizer wins Norvasc patent challenge by Mylan

Pfizer said today that a federal court in the Western District of Pennsylvania (Pittsburgh) has upheld the company's U.S. patent covering the active ingredient in Norvasc

27 Feb 2007

Study shows Diovan reduced urinary protein excretion in patients with type 2 diabetes and high blood pressure

In patients with high blood pressure and type 2 diabetes, the blood pressure-lowering medication Diovan (valsartan) significantly reduced urinary protein excretion, with high doses providing the greatest sustained reduction , according to data presented at the Amer ican Heart Association's (AHA) Annual Scientific Sessions.

13 Nov 2006

Diabetes risk down three times with newer hypertension drugs

According to researchers patients given a mix of modern blood pressure drugs are one-third less likely to develop diabetes than those on older pills.

7 Sep 2006

One of the largest Japanese cardiovascular trials confirms angiotensin receptor blockade protects people who have a wide range of cardiovascular diseases

The first controlled large-scale intervention trial of angiotensin receptor blockade in Japanese patients has confirmed that the cardiovascular protective effects of the drug valsartan is greater than to those seen with other therapies giving the same level of blood pressure control.

5 Sep 2006